Sergio Lupo

Rosario, S, AR 
Rosario, S, AR 

Overview

Sergio Lupo practices practicing medicine in Rosario, Argentina.

His clinical expertise encompasses Undifferentiated Pleomorphic Sarcoma, Spastic Paraparesis, Ganglion Cyst, and HIV/AIDS.

He is actively involved in clinical research, co-authoring 10 peer reviewed articles and participating in 3 clinical trials.

Gender

Male

Locations

Rosario, S, Argentina
Other Locations
Cordoba, X, Argentina

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase 2a Multicentre, Randomized, Open-Label, Two-Part Adaptive Design Study to Evaluate the Antiviral Effect, Safety and Tolerability of GSK3810109A, an HIV-1 Specific Broadly Neutralizing Human Monoclonal Antibody in Antiretroviral-naïve HIV-1-Infected Adults
A Phase 2a Multicentre, Randomized, Open-Label, Two-Part Adaptive Design Study to Evaluate the Antiviral Effect, Safety and Tolerability of GSK3810109A, an HIV-1 Specific Broadly Neutralizing Human Monoclonal Antibody in Antiretroviral-naïve HIV-1-Infected Adults
Enrollment Status: Completed
Publish Date: October 15, 2024
Intervention Type: Biological
Study Drug: GSK3810109A
Study Phase: Phase 2
A Phase IIIB/IV Randomised Open-label Trial Comparing Dolutegravir With Pharmaco-enhanced Darunavir Versus Dolutegravir With Predetermined Nucleosides Versus Recommended Standard of Care ART Regimens in Patients With HIV-1 Infection Failing First Line Therapy.
A Phase IIIB/IV Randomised Open-label Trial Comparing Dolutegravir With Pharmaco-enhanced Darunavir Versus Dolutegravir With Predetermined Nucleosides Versus Recommended Standard of Care ART Regimens in Patients With HIV-1 Infection Failing First Line Therapy.
Enrollment Status: Unknown
Publish Date: April 18, 2023
Intervention Type: Drug
Study Drugs: NRTIs, Dolutegravir, Darunavir, Ritonavir
Study Phase: Phase 4
An International Observational Study to Characterize Adults With Influenza or Other Targeted Respiratory Viruses
An International Observational Study to Characterize Adults With Influenza or Other Targeted Respiratory Viruses
Enrollment Status: Completed
Publish Date: August 18, 2017
View 2 Less Clinical Trials

10 Total Publications

Safety and efficacy of switching to bictegravir-lenacapavir versus continuing bictegravir-emtricitabine-tenofovir alafenamide in virologically suppressed people with HIV-1 (ARTISTRY-2): a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial.
Safety and efficacy of switching to bictegravir-lenacapavir versus continuing bictegravir-emtricitabine-tenofovir alafenamide in virologically suppressed people with HIV-1 (ARTISTRY-2): a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial.
Journal: The lancet. HIV
Published: March 17, 2026

Frequently Asked Questions about Sergio Lupo

Is Sergio Lupo a top-rated expert for Undifferentiated Pleomorphic Sarcoma?

MediFind is an objective health platform that identifies experts based on real-world data. Sergio Lupo is classified as an Experienced expert for Undifferentiated Pleomorphic Sarcoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Sergio Lupo participate in research or clinical trials?

Yes. Sergio Lupo has published 10 articles and abstracts on conditions like Undifferentiated Pleomorphic Sarcoma. You can view a list of Sergio Lupo's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Lupo's expertise for a condition
ConditionClose
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile